Testing NY-ESO-1 T-cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old, and you understand and can sign consent.
- Your cancer is a solid tumor that has spread or come back, and it is confirmed by biopsy.
- Your cancer has been tried with standard treatments and is no longer responding (or has progressed).
- Your tumor has NY-ESO-1 on it at the required level (at least 25% positive cells, intensity “++” or higher).
- You have the right blood type marker: HLA-A2, but not HLA-A*0203.
- Your blood, liver, kidney, clotting tests, and heart scan meet the safety thresholds, and you can provide fresh or stored tumor tissue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy for people with advanced solid tumors (lung, liver, colorectal, or breast cancer). It aims to use your own immune cells to fight the cancer, and might help if standard treatments have stopped working.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests an experimental treatment called Super1 TCR-T, which is a type of immunotherapy designed to attack tumors that have a specific protein (NY-ESO-1). It is for people with advanced solid tumors whose first treatment has stopped working and who also have a certain genetic marker (HLA-A*02).
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.